According to Greystone Associates, a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology assessment - is addressing the possible challenges facing cancer vaccines coming to market in the statement, "In spite of the market hype and wishful thinking, the results of clinical trials for cancer vaccines to date have been mixed and often disappointing. While the challenge of creating and successfully proving the efficacy of a vaccine that can effectively treat America's second-deadliest disease is perhaps without medical precedent, a close look at the dynamics and regulatory environment of the clinical trial process provides insight into possible reasons why the first approvable, truly therapeutic cancer vaccine may still be years away." Seems the first problem is proving the efficiency of cancer vaccines in clinical trails, given results that can not be measured with true analytical accuracy or precision among patients. The second problem appears to be governmental and corporate.
 
"Cancer vaccines are playing by rules which in some ways place them at a distinct disadvantage relative to the therapeutic value they have been designed to deliver," explains George Perros, Greystone Associates Managing Director. "These issues, which will require a strong working relationship between vaccine developers and key FDA and NCI decision makers to resolve, must be addressed if the promise of cancer vaccines is to be fully realized."

I am not the least bit interested in easing the way for companies in a rush to get drugs to market so they can enhance their financial bottom line. I want drugs that make it to market to be thoroughly tested and proven safe. But I will be aggravated to learn that there are factors slowing the process that could have been avoided.